ALVO Alvotech

$5.14

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Alvotech

Alvotech Holdings SA, develops and manufactures biosimilars for global markets. The company is headquartered in Iceland.

Website: https://www.alvotech.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1898416
Address
9, RUE DE BITBOURG, LUXEMBOURG, LU
Valuation
Market Cap
$2.50B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
0.00
Performance
EPS
$-0.87
Dividend Yield
—
Profit Margin
-47.10%
ROE
0.00%
Technicals
50D MA
$10.82
200D MA
$11.79
52W High
$14.76
52W Low
$7.35
Fundamentals
Shares Outstanding
302M
Target Price
$18.00
Beta
-0.05

ALVO EPS Estimates vs Actual

● Estimated
● Actual

ALVO News & Sentiment

Nov 21, 2025 • Zacks Commentary NEUTRAL
New Strong Sell Stocks for Nov. 21st
ALVO, AKZOY and ALG have been added to the Zacks Rank #5 (Strong Sell) List on November 21, 2025.
Nov 20, 2025 • GlobeNewswire NEUTRAL
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® ( golimumab )
Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited ( "Advanz Pharma" ) , a UK headquartered global pharmaceutical company with a strategic focus on specialty, ...
Nov 20, 2025 • GlobeNewswire NEUTRAL
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® ( golimumab )
REYKJAVIK, Iceland and LONDON, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited ( "Advanz Pharma" ) , a UK headquartered global ...
Nov 13, 2025 • Benzinga NEUTRAL
Ardent Health, KinderCare Learning, Ibotta And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Absci ( NASDAQ:ABSI ) , Alvotech ( NASDAQ:ALVO )
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday. Shares of Ardent Health, Inc. ( NYSE:ARDT ) fell sharply in pre-market trading after the company reported third-quarter earnings below estimates and lowered its FY2025 GAAP EPS guidance.
Nov 13, 2025 • Zacks Commentary NEUTRAL
New Strong Sell Stocks for Nov. 13
AMRK, ALVO and GPK have been added to the Zacks Rank #5 (Strong Sell) List on Nov. 13, 2025.
Nov 12, 2025 • Zacks Commentary NEUTRAL
Alvotech ( ALVO ) Reports Q3 Loss, Misses Revenue Estimates
Alvotech (ALVO) delivered earnings and revenue surprises of -140.00% and -11.60%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Sentiment Snapshot

Average Sentiment Score:

0.128
50 articles with scored sentiment

Overall Sentiment:

Neutral

ALVO Reported Earnings

Aug 13, 2025
Jun 30, 2025 (Post market)
0.03 Surprise
  • Reported EPS: $0.03
  • Estimate: $-0.00
  • Whisper: —
  • Surprise %: 1404.3%
May 07, 2025
Mar 31, 2025 (Pre market)
0.32 Surprise
  • Reported EPS: $0.35
  • Estimate: $0.03
  • Whisper: —
  • Surprise %: 1066.7%
Mar 26, 2025
Dec 31, 2024 (Post market)
-0.21 Surprise
  • Reported EPS: $-0.24
  • Estimate: $-0.03
  • Whisper: —
  • Surprise %: -700.0%
Nov 13, 2024
Sep 30, 2024 (Post market)
-0.42 Surprise
  • Reported EPS: $-0.48
  • Estimate: $-0.06
  • Whisper: —
  • Surprise %: -700.0%
Aug 15, 2024
Jun 30, 2024 (Post market)
0.3 Surprise
  • Reported EPS: $0.28
  • Estimate: $-0.02
  • Whisper: —
  • Surprise %: 1500.0%
May 21, 2024
Mar 31, 2024 (Post market)
-0.81 Surprise
  • Reported EPS: $-0.89
  • Estimate: $-0.08
  • Whisper: —
  • Surprise %: -1012.5%
Mar 20, 2024
Dec 31, 2023 (Post market)
-1.26 Surprise
  • Reported EPS: $-1.22
  • Estimate: $0.04
  • Whisper: —
  • Surprise %: -3150.0%
Nov 28, 2023
Sep 30, 2023 (Post market)
-0.75 Surprise
  • Reported EPS: $-0.82
  • Estimate: $-0.07
  • Whisper: —
  • Surprise %: -1071.4%
Aug 30, 2023
Jun 30, 2023 (Post market)
0.0 Surprise
  • Reported EPS: $-0.14
  • Estimate: $-0.14
  • Whisper: —
  • Surprise %: 0.0%

Financials